DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, has announced its consolidated financial results for the year ended December 31, 2025. The company reported a cash position of $60 million, which is expected to fund operations through the second half of 2027. The financial results reflect an increase in cash and short-term investments from $44.1 million in 2024 to $59.9 million in 2025, primarily due to net proceeds from a private placement and an at-the-market offering program. However, the company also reported a net loss of $32.8 million for 2025, compared to a net loss of $24.4 million in 2024, indicating increased operational expenses primarily driven by ongoing clinical trials. The company is actively advancing its clinical programs, particularly in preeclampsia and acute ischemic stroke, with several trials currently enrolling participants. Notably, DiaMedica received regulatory approval from Health Canada to initiate a Phase 2 study for DM199 in early-onset preeclampsia. The company plans to host a conference call on March 31, 2026, to discuss these results and provide further insights into its business strategy and operational execution moving forward.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.